Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended		6 Months Ended
		Feb. 22, 2024	May 31, 2024	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024		Jun. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							66,720
Proceeds from common stock							$ 984		$ 1,166
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							300,001
Increase in available for grant							139,863
Number of common stock purchased					34,332	38,216
Proceeds from common stock					$ 62	$ 182
Treasury stock						12,590
Increase in reserve stock				166,667
Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,500,000
Increase in available for grant							395,886
Number of common stock purchased					511,884	231,987
Proceeds from common stock					$ 353	$ 276
Increase in reserve stock				500,000
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,835,970
Increase in available for grant				432,452			77,379
Number of stock options outstanding							1,235,049	[1]		1,192,458
Granted	[2]						79,500
Weighted average fair value of stock options							$ 1.47		$ 5.25
2014 Equity Plan [Member] | Parent Company [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		59,500
Weighted average exercise price		$ 1.85
2014 Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		390,000
Aggregate fair value		$ 700
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							8,744,626	[3]		5,504,383
Granted	[4]						3,519,000
Weighted average fair value of stock options							$ 0.80		$ 0.87
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							14,324,038
Increase in available for grant				2,680,038			768,595
Granted		2,895,000					523,300
Weighted average exercise price		$ 1.25
Number of restricted stock awards granted, shares							50,000
2018 Equity Plan [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted			1,600,000
Aggregate fair value			$ 1,500

[1] The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of June 30, 2024 and December 31, 2023.

[2] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.

[3] The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of June 30, 2024 and December 31, 2023.

[4] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.